Table 1.
Characteristics of patients having undergone allogeneic HCT.
| N = 236 | |
|---|---|
| Stem cell source | |
| BM (bone marrow) | 37 (15.7) |
| PB (peripheral blood) | 186 (78.8) |
| CB (cord blood) | 4 (1.7) |
| Missing | 9 (3.8) |
| HLA match | |
| Matched family | 78 (33.0) |
| Unrelated | 111 (47.0) |
| Mismatched family | 35 (14.8) |
| Missing | 12 (5.1) |
| Conditioning | |
| Myeloablative | 108 (45.8) |
| Reduced | 111 (47.0) |
| Missing | 17 (7.2) |
| In-vivo T-cell depletion | |
| No | 109 (46.2) |
| Yes | 121 (51.3) |
| Missing | 6 (2.5) |
| aGvHD at time of COVID-19 | |
| no aGvHD/grade 1 | 132 (55.9) |
| grade 2–4 | 12 (5.1) |
| Chronic GvHD at time of COVID-19 | |
| No (never) | 137 (58.0) |
| Yes, ongoing | 77 (32.6) |
| Resolved | 12 (5.1) |
| Missing | 10 (2.8) |
| Corticosteroids | |
| No | 133 (56.3) |
| Yes | 88 (37.3) |
| Missing | 15 (6.3) |